This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

This database contains 438 studies, archived under the term: "USA"

Click here to filter this large number of results.

PF-04494700, an oral inhibitor of receptor for advanced glycation end products (RAGE), in Alzheimer disease

Objective: To evaluate the safety and tolerability of PF-04494700, an oral inhibitor of receptor for advanced glycation end products, in patients with mild-to-moderate dementia of the Alzheimer type.; Methods: Patients aged 50 years and older who met the National Institute of Neurological and Communicative Diseases and Stroke/Alzheimer’s Disease and Related Disorders Association criteria for Alzheimer […]

Evaluating the cognitive effects of donepezil 23 mg/d in moderate and severe Alzheimer’s disease: analysis of effects of baseline features on treatment response

Background: Treatment of Alzheimer’s disease with acetylcholinesterase inhibitors can result in symptomatic benefits, but patients often show variable responses. The objective of this post hoc analysis was to investigate relationships between easily identifiable baseline characteristics/demographics and cognitive response in patients treated with either donepezil 23 mg/d or 10 mg/d and to identify factors potentially influencing response.; Methods: […]

Early 11C-PIB frames and 18F-FDG PET measures are comparable: a study validated in a cohort of AD and FTLD patients

Unlabelled: The availability of new PET ligands offers the potential to measure fibrillar β-amyloid in the brain. Nevertheless, physiologic information in the form of perfusion or metabolism may still be useful in differentiating causes of dementia during life. In this study, we investigated whether early (11)C-Pittsburgh compound B ((11)C-PIB) PET frames (perfusion (11)C-PIB [pPIB]) could […]

Safety and efficacy of methylphenidate for apathy in Alzheimer’s disease: A randomized, placebo-controlled trial

Objective: In a recent crossover trial, methylphenidate treatment decreased apathy in Alzheimer’s disease. We further assessed this finding in the Apathy in Dementia Methylphenidate Trial (ADMET). Method: Six-week, randomized, double-blind, placebo-controlled multicenter trial enrolling Alzheimer’s disease participants (NINCDS-ADRDA criteria) with apathy assigned to methylphenidate 20 mg daily or placebo, conducted from June 2010 to December […]

PRECREST: a phase II prevention and biomarker trial of creatine in at-risk Huntington disease

Objective: To assess the safety and tolerability of high-dose creatine, the feasibility of enrolling premanifest and 50% at-risk subjects in a prevention trial, and the potential of cognitive, imaging, and blood markers.; Methods: Sixty-four eligible consenting participants were randomly allocated (1:1) to 15 g twice daily of creatine monohydrate or placebo for a 6-month double-blind […]

Physical activity and cognitive functioning in the oldest old: Within- and between-person cognitive activity and psychosocial mediators

The current study examines the role of social contact intensity, cognitive activity, and depressive symptoms as within- and between-person mediators for the relationships between physical activity and cognitive functioning. All three types of mediators were considered simultaneously using multilevel structural equations modeling with longitudinal data. The sample consisted of 470 adults ranging from 79.37 to […]

A randomized controlled trial of an activity specific exercise program for individuals with Alzheimer disease in long-term care settings

Objective: To determine whether an activity specific exercise program could improve ability to perform basic mobility activities in long-term care residents with Alzheimer disease (AD).; Design: Randomized, controlled, single-blinded clinical trial.; Setting: Residents of 7 long-term care facilities.; Participants: Eighty-two long-term care residents with mild to severe AD.; Intervention: An activity specific exercise program was […]

Galantamine treatment in outpatients with mild Alzheimer’s disease

Objective: To assess long-term effectiveness of galantamine in community-dwelling persons with mild Alzheimer’s disease.; Methods: Prospective open-label trial including patients with mild AD (NINCDS-ADRDA criteria) treated with galantamine for up to 36 months. Outcome parameters included ADAS-cog/11, Bayer-ADL scale (self- and caregivers’ ratings), 10-item NPI and CGI-change, safety and tolerability measures. Data are presented based […]

Cognitive effects of quetiapine in a patient with dementia with Lewy bodies

A recent large-scale randomized controlled clinical trial, the Clinical Antipsychotic Trials of Intervention Effectiveness-Alzheimer’s Disease study, found a significant worsening of cognitive functioning in a sample of patients with Alzheimer’s disease. To date there have been no equally powered studies examining the cognitive effects of atypical antipsychotics in patients with dementia with Lewy bodies, the […]

Application of immunosignatures to the assessment of Alzheimer’s disease

Objective: Accurate assessment of Alzheimer’s disease (AD), both presymptomatically and at different disease stages, will become increasingly important with the expanding elderly population. There are a number of indications that the immune system is engaged in AD. Here we explore the ability of an antibody-profiling technology to characterize AD and screen for peptides that may […]

Try searching our database by another keyword...

To make a new query of the database, please enter your search terms below: